CTR9-Mediated JAK2/STAT3 Pathway Promotes The Proliferation, Migration and Invasion of Human Glioma Cells

Yang Xu  
Nanjing Brain Hospital

Jiaguo Chen  
Nanjing Jinling Hospital: East Region Military Command General Hospital

Gao He  
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Yuhai Zhang  (yhzhangnj@yeah.net)  
Nanjing Brain Hospital  https://orcid.org/0000-0003-0883-8695

Research

Keywords:  Glioma, CTR9, JAK2, STAT3

DOI:  https://doi.org/10.21203/rs.3.rs-524456/v1

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

CTR9 (Cln three requiring 9) has been reported to be implicated in protein modification and oncogenesis of several human cancers. However, the protein expression and mechanism of CTR9 in glioma progression remain unclear.

Methods

We analyzed mRNA expression of CTR9 and CTR9-related survival curves in the public database. Then we detected CTR9 expression in glioma tissues and constructed U251 and U87 cells with stable silencing or overexpression of CTR9. Cell function tests and Western blot were conducted to explore the effects of CTR9 on glioma proliferation, invasion and migration, as well as the specific mechanism. All the data was presented as means ± SEM. Two-sample t-test and one-way analysis of variance (ANOVA) were used to identify whether there was a significant difference between each group of data.

Results

We found that CTR9 was overexpressed in glioma and inversely associated with glioma patient survival. The results manifested that knockdown of CTR9 suppressed the proliferation, migration and invasion of glioma cells, while overexpression facilitated them. The underlying molecular mechanism may involve the regulation of JAK2/STAT3 pathway by CTR9.

Conclusion

Our present study indicates that CTR9 is highly expressed in glioma and related to glioma grading and prognosis. CTR9 regulates malignant behaviors of glioma cells by activating JAK2/STAT3 pathway. Therefore, CTR9 is a promising biomarker for the diagnosis, targeted therapy and prognosis evaluation of glioma.

Introduction

Glioma is the most common malignant tumor of the central nervous system with rapid progress, strong aggression and high rate of relapse[1]. Despite increasing progress in surgery, chemotherapy and radiotherapy, the expected survival time is only 12 to 15 months for late diagnosis and advanced stages [2, 3]. However, molecular targeted agents have therapeutic effects in the treatment of malignant tumors, such as EGFR- and ALK-sensitive lung cancer and VEGF-sensitive colorectal cancer [4, 5]. Monoclonal antibodies and tyrosine kinase inhibitors have played an important role in the treatment of breast cancer, gastrointestinal stromal tumor, and melanoma as the main targeted therapy agents [6–8]. Candidates for
targeted therapy include tumor growth factor receptor, signal transduction molecule, apoptosis regulatory factor, proteolytic enzyme and vascular endothelial growth factor. Hence, explorations in the molecular pathological mechanism of glioma and sequentially appropriate biomarker selection are indispensable to precise treatment of glioma.

Paf1C, composed of Paf1, Leo1, CTR9, Cdc73 and Rtf1, is involved in the malignant progression of many tumors, such as pancreatic carcinoma, ovarian cancer, Wilms tumor and breast cancer [9, 10]. Among the five subunits, CTR9 independently plays significant roles in many biological processes of tumor cells, such as transcription, ubiquitination and cell cycle. Interestingly, CTR9 functions as a tumor suppressor in Wilms cancer [11], however, the expression of CTR9 is up-regulated in breast carcinoma [12, 13]. Till now, whether CTR9 plays as a tumor promoter or suppressor in glioma cells awaits investigation and clarification.

Former researches have found that the activity of STAT3 in tumors was abnormally activated with high frequency, such as glioma, liver cancer, colon cancer, breast cancer, lung cancer and stomach cancer [14–19], its activation degree is significantly related to the poor prognosis of cancer patients. The JAK2 / STAT3 pathway is a key pathway for STAT3 signal transduction and transcriptional activation. Studies have shown that the JAK and STAT were over-expressed in most malignant tumors [20, 21], especially the abnormal activation of STAT3. Normally, STAT3 functions in the cytoplasm, it was transferred into the nucleus once activated and caused abnormal transcription of target genes. STAT3 can facilitate the development of malignant tumors by regulating downstream molecules, such as c-Myc, cyclin-D1, MMP-2, VEGF, Bcl-2 and Bax [22, 23]. Through its own functions and its regulation of downstream molecules, it is involved in the process of the proliferation, migration and invasion of various tumors [24–26]. Therefore, we speculate that CTR9-mediated JAK2/STAT3 pathway may explain the malignant behaviors of glioma.

In our study, we first detected the expression of CTR9 protein in glioma patients’ tissues and glioma cell lines by western blotting assay. Then, the role of CTR9 in glioma was studied through a variety of functional experiments. Finally, we proved that CTR9 facilitates proliferation, migration and invasion through regulating JAK2/STAT3 pathway.

**Materials And Methods**

**Antibodies**

Antibody against CTR9 was purchased from Cell Signaling Technology (Danvers, MA, USA). JAK2, p-JAK2, STAT3, p-STAT3 and β-actin antibodies were bought from Proteintech (Wuhan, Hubei, China).

**Tissue samples**

Twenty-two fresh brain tissue specimens from glioma and six fresh brain tissue specimens from traumatic brain injury were selected randomly from the specimen repository in Nanjing Brain Hospital. All
tissues were taken from the central site of the resected tumors with typical morphology and pathologically confirmed diagnosis.

The selected samples included non-tumor group (6 cases), grade II group (8 cases), grade III group (8 cases) and grade IV group (6 cases), according to the WHO tumor classification standard.

**Cell culture**

The glioma cell lines U251, T98G and human embryonic kidney cell line HEK293T were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. All cells were cultured in DMEM with 10% fetal bovine serum in a 37°C constant temperature incubator containing 5% CO2.

**Construction of lentivirus**

Three short hairpin RNAs (shRNAs) were designed to knock down CTR9 and synthesized as followings:

shCTR-F1: gatccgCCTCCAGAGAGTTCTCAATAATTTCAGAGAAATTATTGAGAATCTCTGGAGGTTTTTTg
shCTR-R1: aattcAAAAAACCTCCAGAGATTCTCAATAATTTCAGAGAAATTATTGAGAATCTCTGGAGGcg

shCTR-F2: gatccgCGTGCAAATGAGACTATTCTTTTCAAGAGAAAGAATAGTCTCATTTTCACGTTTTTTg
shCTR-R2: aattcAAAAAACGTGCAAATGAGACTATTCTTTTCAAGAGAAAGAATAGTCTCATTTTCACGcg

shCTR-F3: gatccGCCATAATTTCATCAAGTGATTTCAAGAGAATCACTTGATGAAATTATGGCTTTTTTg
shCTR-R3: aattcAAAAAACCCATAAATTTCATCAAGTGATTTCAAGAGAATCACTTGATGAAATTATGGCg

**Establishment of U251 and T98G cell lines**

Control, shCTR9#3, GFP and GFP-CTR9 plasmids were co-transfected with helper plasmids pMD2.G and pSPAX2 in HEK293T cells, respectively. Virus supernatants were collected 48 hours after transfection. U251 and T98G cells were infected by obtained lentiviruses and stably expressed Control, shCTR9#3, GFP and GFP-CTR9 after puromycin filtration.

**EdU assay**

Cells at the logarithmic phase were inoculated into 96-well plates. EdU assay was conducted after overnight culture. Diluted reagent 5-ethynyl-20-deoxyuridine was added into each well and cells were incubated at 37°C for 2 hours. The cells were washed with PBS twice and fixed with 4% paraformaldehyde at room temperature for 30 minutes. Afterwards, the cells were incubated with glycine and 0.5% TritonX-100 for 10 and 30 minutes, respectively. Apollo® reagent was added into each well and cells were incubated in dark for 30 minutes. After dealt with 0.5% TritonX-100 and methanol, the nuclei of the cells were dyed with Hoechst for 20 minutes and photographed by a fluorescent microscopy.
**Cell viability assay**

Cell suspension was inoculated into 96-well plates. CCK-8 assay was conducted after overnight culture. 10 μL CCK-8 reagent was applied to each well (Be careful not to form bubbles in the well) and the absorbance at 450nm was measured with a SynergyMx Multi-Mode Microplate Reader (Biotek, Winooski, VT) after reaction for 4 hours at 37°C.

**Transwell migration and invasion assays**

To assess invasion ability, the upper chamber of each filter was covered with 10μg Matrigel (BD, San Jose, CA, USA), which was evenly spread and placed in a 37°C incubator for 2 h. The serum-free cell suspension was then added into the filter and the lower chamber was filled with 10% FBS. After 30 hours of incubation at 37°C, the non-invasive cells were swabbed from the upper chamber. Then cells on the lower side of the filter were fixed with 4% paraformaldehyde for 30 minutes and dyed with 0.03% crystal violet solution for 10 minutes. Three fields of adherent cells in each well were randomly photographed and counted. The same experiment was conducted to assess migration ability except for filters pre-coated with Matrigel.

**Western blot**

The same amount of proteins were placed on 10% SDS-PAGE and then transferred to PVDF membrane after the required strips appeared. The membrane was sealed with 3% BSA for 1 hour at room temperature and cut according to the molecular weight. The membranes were placed into tubes containing primary antibodies at 4°C overnight and secondary antibodies at room temperature for 1 hour. The antibodies were detected by ECL or DAB. Image J analysis software was used to analyze the strips.

**Results**

**CTR9 protein is highly expressed in human glioma tissues**

To explore the role of CTR9 in human gliomas, we used GEPIA Web server to analyze the expression of CTR9 mRNA in glioma and the relationship between CTR9 expression and survival of glioma patients. The results showed that CTR9 mRNA expression was significantly increased in both low grade glioma (LGG) and glioblastoma (GBM) tissues, compared with normal brain tissues (Fig. 1A). Also, we found that high expression of CTR9 in glioma patients indicated poor prognosis ($P<0.05$, Fig. 1B). To verify these data, we sequentially detected CTR9 expression in non-tumor and tumor brain tissues by Western blot. It showed that CTR9 expression level in glioma tissues was significantly increased compared with non-tumor tissues, particularly in Grade IV gliomas (Fig. 1C and D). These obtained results revealed that both mRNA and protein level of CTR9 were overexpressed in human glioma tissues, indicating that CTR9 may act as an important role in human gliomas.

**Down-regulation of CTR9 restrains the proliferation, migration and invasion of glioma cells**


To study the effects of CTR9 on malignant behaviors of glioma cells, we downregulated CTR9 expression in glioma cells by its specific shRNAs and reevaluated the proliferation, migration and invasion abilities of glioma cells. First, we constructed three shRNAs (shCTR9#1, shCTR9#2 and shCTR9#3) and found shCTR9#3 owned highest efficiency in suppressing CTR9 expression (Fig. 2A-C). Then, we cultured the stable down-regulated CTR9 and control cell lines with lentivirus packaged by shCTR9#3 and control. After that, we studied whether silencing CTR9 has a negative or positive effect on cell proliferation.

The EdU incorporation assay showed that the EdU-positive cells in CTR9-silenced U251 cells decreased by 50%, while decreased by 25% in CTR9-silenced T98G cells, compared with their respective control group (Fig. 2D and E). Also, the CCK-8 assay showed down-regulation of CTR9 suppressed cell viability in glioma cells (Fig. 2F and G). The results above showed that CTR9 was involved in the proliferation of human glioma cells and down-regulation of CTR9 inhibited the proliferation of glioma cells.

To explore the role of CTR9 on the migration and invasion of glioma cells, we conducted transwell assay. The transwell migration assay (-Matrigel) indicated that down-regulation of CTR9 suppressed the cell migration in U251 and T98G cells (Fig. 2H and I). The transwell invasion assay(+ Matrigel) showed the number of invasive CTR9-silenced U251 and T98G cells decreased by 50% and 45%, compared to the control group (Fig. 2J and K). Repeated results manifested that silencing CTR9 inhibits migration and invasion of glioma cells.

**Overexpression of CTR9 promotes the proliferation, migration and invasion of human glioma cells**

Additionally, in order to further clarify the effect of CTR9 on glioma cell proliferation, migration and invasion, we overexpressed GFP-CTR9 in U251 and T98G cells and explore the effects from another angle. The expression efficiency was testified by Western blotting (Fig. 3A). EdU incorporation assay showed that EdU-positive cells in CTR9-overexpressed U251 and T98G cells increased by 50% and 30% compared with respective GFP group (Fig. 3B and C). Also, CCK-8 assay manifested that CTR9 promoted the proliferating ability of U251 and T98G cells compared with the control groups. The transwell migration assay (-Matrigel) showed that overexpression of CTR9 promoted the cell migration in U251 and T98G cells (Fig. 3F and G). The transwell invasion (+ Matrigel) assay displayed that the number of invading U251 and T98G cells increased by 80% and 82% after CTR9 overexpression (Fig. 3H and I). These results suggested that CTR9 is involved in the proliferation, migration and invasion of human glioma cells and acts as a tumor promoter.

**CTR9 promotes the proliferation, migration and invasion of human glioma cells by regulating JAK2/STAT3 pathway**

Previous reports have shown that CTR9 could activate STAT3 signaling [27]. Furthermore, it is acknowledged that JAK2/STAT3 pathway is involved in growth and motility of human cancers [28–30].Based on these, we supposed that CTR9-mediated JAK2/STAT3 pathway may play a significant role in proliferation, migration and invasion of human glioma cells. We confirmed our inference by Western Blot. The results showed that STAT3 and p-STAT3 were decreased in CTR9 knockdown U251 and T98G
cells, however, the expression of STAT3 and p-STAT3 were increased in CTR9 overexpressed U251 and T98G cells (Fig. 4A-C). Moreover, the expression of JAK2 and p-JAK2, the upstream regulator of STAT3, was decreased upon silencing CTR9, but enhanced upon overexpressing CTR9 (Fig. 4D-F). Furthermore, to confirm that CTR9 regulates STAT3 by activating JAK2, we applied JAK2 inhibitor SB1317 to conduct the rescue experiment. As expected, overexpression of CTR9 up-regulated JAK2, p-JAK2, STAT3 and p-STAT3. However, this up-regulation could be significantly blocked by JAK2 inhibitor SB1317 (Fig. 5A-C). The results demonstrated that STAT3 and p-STAT3 upregulation induced by CTR9 were attributed to JAK2 and p-JAK2 activation. In addition, we conducted CCK-8 and transwell assays to confirm this in the presence of the JAK2 inhibitor. As the results showed, JAK2 inhibitor SB1317 blocked cell proliferation (Fig. 5D and E), migration (Fig. 5F and G) and invasion (Fig. 5H and I). In all, the results expounded that CTR9-mediated JAK2/STAT3 pathway could accelerate proliferation, migration and invasion of glioma cells.

Discussion

CTR9 is a multi-functional gene that is implicated in many cellular processes such as cell cycle, transcription, neurogenesis and embryonic organogenesis [10, 11, 31, 32]. Former researches have shown that CTR9 functions as a tumor suppressor in Wilms tumor while drives ERα-positive breast tumorigenesis [12], which indicates that CTR9 is a potential candidate for human tumor biomarkers. However, the expression of CTR9 and its clinical relevance in glioma patients have never been clearly elaborated. In our present study, we detected that CTR9 was up-regulated in human glioma tissues compared with tissues derived from normal brain. In addition, we drew a conclusion that high expression of CTR9 was strongly associated with poor prognosis of glioblastoma patients through public database analysis. We clarified that up-regulation of CTR9 in glioma cells could accelerate proliferation, migration and invasion of glioma cells by regulating the JAK2/STAT3 pathway. These findings suggest that CTR9 exerts as a tumor-promoting role in glioma and is a promising therapeutic strategy in human brain glioma.

It is widely acknowledged that silencing of specific tumor suppressor genes and activation of certain oncogenes are responsible for the occurrence and malignant progression of glioblastoma [33, 34]. In particular, JAK2/STAT3 pathway is deeply involved in the survival and motion of tumor cells [35]. The excessive activation of JAK2 signaling in glioma is accelerated by abnormal signals from upstream regulators [36, 37]. This usually involves any gain-of-function mutations or up-regulation of upstream inhibitors, and, on the other hand, any loss-of-function mutation or down-regulation of the upstream inhibitors. In this study, we found that CTR9 could promote glioma cell proliferation, migration and invasion by modulating JAK2/STAT3 pathway. That is to say, up-regulation of CTR9 may be an significant event in the development and malignant progression of human glioma.

STAT3 plays a strong inhibitory role on cell apoptosis through JAK2/STAT3 pathway and its continuous activation of cells is deeply involved in the occurrence and progression of human malignant tumors [38]. Phosphorylated Stat3, once transferred into the nucleus, can regulate the transcription of some target
genes involved in basic physiological functions and induce the abnormal expression of genes closely related to cell proliferation, differentiation and apoptosis, such as Bcl-XL and c-Myc, promoting cell proliferation and malignant transformation [39]. In the present study, we found that Stat3 and p-STAT3 were significant up-regulated upon CTR9-induced activation of JAK2 pathway. Besides, the overexpression of STAT3 and acceleration of glioma cell proliferation, migration and invasion induced by up-regulation of CTR9 could be distinctly blocked by JAK2 inhibitor.

Taken together, we affirmed the association between the CTR9-mediated JAK2/STAT3 pathway and the malignant behaviors of glioma. Our findings provided a basis for early diagnosis, potential therapeutic target and prognosis evaluation in glioma. However, more sequent researches are urgent to be conducted to clarify the precise mechanisms of CTR9 mediated activation of JAK2/STAT3 pathway in human glioma.

Declarations

Acknowledgements

We would like to thank Dr. Liang Zhao for critical review of this manuscript.

Authors’ contributions

Study design: Yuhai Zhang and Yang Xu. Experiments: Yang Xu and Jiaguo Chen. Data analysis: Jiaguo Chen and Gao He. Manuscript preparation: Yang Xu. Manuscript review: Yuhai Zhang. The manuscript was approved by the authors.

Funding

The authors have no funding interests to declare.

Availability of data and materials

Data can be required from the corresponding author.

Ethics approval and consent to participate

Informed consents were acquired from each patient or their families and passed by the Ethics Committee of the Affiliated Brain Hospital of Nanjing Medical University. Case number: 2020-KY076-05

Consent for publication

Written informed consent for publication was obtained from all participants.

Conflict of interests

The authors declare no competing interests.
References

1. Arevalo OJ, Valenzuela R, Esquenazi Y, Rao M, Tran B, Zhu J, Bhattacharjee M, Fonseca P, Doyle N, Riascos RF. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Practical Approach for Gliomas, Part 1. Basic Tumor Genetics. Neurographics. 2017;7:334–43.

2. Ning W. Edward, Chu, Peter, Wipf, John, Schmitz: Protein kinase d as a potential chemotherapeutic target for colorectal cancer. Molecular cancer therapeutics 2014.

3. Tal S, Uri, Rozovski, Kenneth R. Hess, Anwar, Hossain, Joy: Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncology 2016.

4. Bowles DW, Weickhardt A, Jimeno A. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. Drugs Today. 2013;49:523–35.

5. Kuifeng, He, Binbin, Cui G, Li H, Wang, Ketao J: The effect of anti-VEGF drugs (bevacizumab and afiblercept) on the survival of patients with metastatic colorectal cancer (mCRC). Oncotargets & Therapy 2012.

6. Carloni S, Fabbri F, Brigliadori G, Ulivi P, Silvestrini R, Amadori D, Zoli W. Tyrosine Kinase Inhibitor, Gefitinib, Lapatinib, Sorafenib, Breast Cancer. Curr Cancer Drug Targets. 2010;10:422–31.

7. Nishida T, Doi T, Naito Y. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert Opinion on Pharmacotherapy 2014.

8. Chi M, Puzanov I. Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors. memo - Magazine of European Medical Oncology. 2012;5:302–8.

9. Tomson BN, Arndt KM. The many roles of the conserved eukaryotic Paf1 complex in regulating transcription, histone modifications, and disease states. Biochimica Et Biophysica Acta. 2013;1829:116–26.

10. Xie Y, Zheng M, Chu X, Chen Y, Xu H, Wang J, Zhou H, Long J. Paf1 and Ctr9 subcomplex formation is essential for Paf1 complex assembly and functional regulation. Nature Communications 2018, 9.

11. Hanks S, Perdeaux ER, Seal S, Ruark E, Mahamdallie SS, Murray A, Ramsay E, Silvana DVD, Zachariou A, De Souza B. Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour. Nat Commun. 2014;5:4398.

12. Zeng H, Xu W. Ctr9, a key subunit of PAFc, affects global estrogen signaling and drives ERα-positive breast tumorigenesis. Genes Dev. 2015;29:2153–67.

13. Hao Z, Li L, Ting CN, Mark H, Paul A, Xuehua Z, Wei X. Systematic identification of Ctr9 regulome in ERα-positive breast cancer. BMC Genomics 2016, 17.

14. Ganguly D, Fan M, Yang CH, Zbytek B, Pfeffer LM. The critical role that STAT3 plays in glioma-initiating cells: STAT3 addiction in glioma. Oncotarget. 2018;9:1640.

15. Chen ZZ, Lan H, Wu YH, Zhai WJ, Gao YF. LncSox4 promotes the self-renewal of liver tumour-initiating cells through Stat3-mediated Sox4 expression. Nat Commun. 2016;7:12598.
16. Jiang R, Wang H, Deng L, Hou J, Shi R, Yao M, Gao Y, Yao A, Wang X, Yu L. **IL-22 is related to development of human colon cancer by activation of STAT3.** Bmc Cancer 2013.

17. Yang SF, Hou MF, Chen FM, Ou-Yang F, Wu YC, Chai CY, Yeh YT. Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy. Bmc Cancer. 2016;16:20.

18. Qian YY, Chai S, Liang Z, Wang Y, You Z. KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer. Molecular Cancer. 2014;13:1-11.

19. Fukui H, Zhang X, Sun C, Hara K, Miwa H. IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling. Br J Cancer. 2014;111:763-71.

20. Yoshikawa T, Miyamoto M, Aoyama T, Soyama H, Goto T, Hirata J, Suzuki A, Nagaoka I, Tsuda H, Furuya K. **JAK2/STAT3 pathway as a therapeutic target in ovarian cancers.** Oncology Letters 2018.

21. Zhang X, Hu F, Li G, Li G, Feng Y. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis. 2018;9:25.

22. Pia I, Ilkka J, Krista-Liisa V, Markku K, Olli S. **The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.** Rheumatology 2015:1103.

23. Darnell J, Kerr I, Stark G. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415-21.

24. Huang W, Dong Z, Wang F, Peng H, Zhang JT. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. Acs Chemical Biology. 2014;9:1188-96.

25. Shen N, Huang X, Li J. Upregulation of miR-129-5p affects laryngeal cancer cell proliferation, invasiveness, and migration by affecting STAT3 expression. Tumor Biology. 2016;37:1789-96.

26. Luo J, Yan R, He X, He J. Constitutive activation of STAT3 and cyclin D1 overexpression contribute to proliferation, migration and invasion in gastric cancer cells. American Journal of Translational Research. 2017;9:5671-7.

27. Youn MY, Yoo HS, Kim MJ, Hwang SY, Choi Y, Desiderio SV, Yoo JY. hCTR9, a Component of Paf1 Complex, Participates in the Transcription of Interleukin 6-responsive Genes through Regulation of STAT3-DNA Interactions. J Biol Chem. 2007;282:34727-34.

28. Marotta LLC, Almendro V, Marusyk A, Shipitsin M, Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44 + CD24− stem cell–like breast cancer cells in human tumors. Journal of Clinical Investigation. 2011;121:2723-35.

29. Cai Lv, Yuan, Huang Z-X. Liu, Dan, Yu, Zhi-Ming, Bai: **Salidroside reduces renal cell carcinoma proliferation by inhibiting JAK2/STAT3 signaling.** Cancer Biomarkers 2016, 17.

30. Liu X, Ji Q, Ye N, Sui H, Zhou L, Zhu H, Fan Z, Cai J, Li Q, Tang CH. Berberine Inhibits Invasion and Metastasis of Colorectal Cancer Cells via COX-2/PGE2 Mediated JAK2/STAT3 Signaling Pathway. Plos One. 2015;10:e0123478.
31. Hyun-Seok Y, Jung-Hwa S, Joo-Yeon Y, Ki KY. CTR9, a Component of PAF Complex, Controls Elongation Block at the c-Fos Locus via Signal-Dependent Regulation of Chromatin-Bound NELF Dissociation. Plos One. 2013;8:e61055.

32. Bahrampour S, Thor S. Ctr9, a Key Component of the Paf1 Complex, Affects Proliferation and Terminal Differentiation in the Developing Drosophila Nervous System. G3 Genesgenetics. 2016;6:3229–39.

33. Xie M, Ji Z, Bao Y, Zhu Y, Xu Y, Wang L, Gao S, Liu Z, Tian Z, Meng Q. PHAP1 promotes glioma cell proliferation by regulating the Akt/p27/stathmin pathway. Journal of Cellular and Molecular Medicine 2018.

34. Yufu, Zhu, Xiang, Zhang L, Wang, Zhe, Ji, Manyi X. Loss of SH3GL2 promotes the migration and invasion behaviours of glioblastoma cells through activating the STAT3/MMP2 signalling. Journal of Cellular & Molecular Medicine 2017.

35. Byun HJ, Darvin P, Dong YK, Sp N, Yang YM. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells. Oncol Rep. 2017;37:3270–8.

36. Colomiere M, Ward AC, Riley C, Trener MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas. British Journal of Cancer.

37. Zhang X, Ding H, Han Y, Sun D, Wang H, Zhai X. The significance of microRNA-184 on JAK2/STAT3 signaling pathway in the formation mechanism of glioblastoma. Oncology Letters 2015.

38. Nizam U, Rae-Kwon K, Ki-Chun Y, Young-Heon K, Yan-Hong C, In-Gyu K, Yongjoon S, Su-Jae L. Persistent activation of STAT3 by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer. Cancer Sci. 2019;106:718–25.

39. Lee JH, Schütte D, Wulf G, Füzesi L, Radzun HJ, Schweyer S, Engel W. Nayernia aK: Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet. 2006;15:201–11.

Figures
Expression of CTR9 in human glioma tissues. A, CTR9 mRNA is overexpressed in both LGG and GBM, compared to normal brain tissues. B, Kaplan-Meier analysis reveals high expression of CTR9 is related to poor survival time. C, Western blotting was used to detect the protein levels of CTR9 in non-tumor brain tissues (6 cases) and human glioma tissues (8 cases for Grade II, 8 cases for Grade III and 6 cases for
Figure 2

Down-regulation of CTR9 inhibits glioma cell proliferation, migration and invasion. A-C, Western blot showed shCTR9#3 had the best silencing efficiency of 3 shRNAs. D and E, EdU incorporation assay demonstrated that the proliferation of U251 and T98G cells was suppressed after down-regulation of
CTR9, compared with the control group, scale bars: 100 μm. F and G, CCK-8 assay reached the similar conclusion as EdU that down-regulation of CTR9 inhibited cell viability of U251 and T98G cells. H and I, Transwell (-Matrigel) assay showed that silencing CTR9 suppressed migration of U251 and T98G cells, scale bars: 500 μm. J and K, Transwell (+Matrigel) assay indicated that silencing CTR9 suppressed invasion of U251 and T98G cells, scale bars: 500 μm. *P<0.05, **P<0.01.

Figure 3
Overexpression of CTR9 promotes glioma cell proliferation, migration and invasion. A, Western blot confirmed successful overexpression of CTR9 in U251 and T98G cells. B and C, EdU incorporation assay demonstrated that the proliferation of U251 and T98G cells was promoted after overexpression of CTR9, compared with the control group, scale bars: 100 μm. D and E, CCK-8 assay showed that overexpression of CTR9 accelerated cell viability of U251 and T98G cells. F and G, Transwell (-Matrigel) assay showed that overexpressing CTR9 promoted migration of U251 and T98G cells, scale bars: 500 μm. H and I, Transwell (+Matrigel) assay indicated that overexpressing CTR9 promoted invasion of U251 and T98G cells, scale bars: 500 μm. *P<0.05, **P<0.01, ***P<0.001.
CTR9 regulates JAK2/STAT3 pathway. A-C, Western blotting assay showed that the expression levels of JAK2, p-JAK2, STAT3 and p-STAT3 in U251-shCTR9#3 and T98G-shCTR9#3 cells were significantly suppressed than those in the control group, respectively. D-F, Western blotting assay confirmed that the expression levels of JAK2, p-JAK2, STAT3 and p-STAT3 in U251 GFP-CTR9 and T98G GFP-CTR9 cells.
were significantly overexpressed than those in the control group, respectively. *P<0.05, **P<0.01, ***P<0.01.

**Figure 5**  

SB1317 notably blocks CTR9 overexpression-induced up-regulation of JAK, p-JAK2, STAT3 and p-STAT3, as well as proliferation, migration and invasion of glioma cells. A-C, Up-regulation of JAK, p-JAK2, STAT3 and p-STAT3 induced by CTR9 overexpression was effectively inhibited by the JAK2 inhibitor SB1317. D-I,
Rescue experiments showed JAK2 inhibitor SB1317 significantly blocked the proliferation, migration and invasion of glioma cells induced by CTR9 up-regulation. *P<0.05, **P<0.01.